Le Lézard
Classified in: Covid-19 virus
Subjects: Product/Service, Survey

New Study: Supply Chains Unprepared to Meet Future Disruption Due to Disconnected Teams, Systems, Processes


Seventy-nine percent of supply chain professionals have to react to unanticipated changes on a regular basis. However, due to siloed or inaccessible information from vendors, outdated manual processes, and disconnected systems and teams across the organization, the vast majority feel unprepared to react to changes quickly. These and other findings were uncovered in a supply chain study from Quickbase, the leading no-code platform for operational agility.

In the last 18 months, supply chains have been more affected than ever by rapid changes and disruptions, largely as a result of the COVID-19 pandemic. The survey, "Building Resiliency Through Supply Chain Visibility," identifies the most critical pain points behind these disruptions, and explores trends around organizations' ability to react to change and identify a more efficient path forward to keep up with the rapid pace of change in today's businesses.

Highlights from the survey include:

"When there's any kind of disruption to a supply chain ? big or small ? it's critical to have access to all data in real-time to make decisions," said Ed Jennings, CEO of Quickbase. "We live in a world where disruption is constant, and organizations need technology that is accessible to teams that are closest to the problems to move quickly ? that's where we come in. Our platform empowers organizations to get real-time insights from their core systems as well as connect teams and data across sources."

Quickbase is designed to promote collaboration by providing visibility to make critical decisions with real-time data. The platform's approach to citizen automation democratizes the ability to create new business applications that solve the most pressing supply chain challenges. Organizations that build a strong practice of citizen development and automation are able to unite data and systems quickly, automate tedious processes and better collaborate across business units and partners.

About the Study

More than 200 enterprise (with 1000+ employees at each organization) supply chain professionals participated in the survey in February 2021. The full survey is available on Quickbase's website.

About Quickbase

Quickbase provides a no-code operational agility platform that enables organizations to improve operations through real time insights and automation across complex processes and disparate systems. Our goal is to help companies achieve operational agility ? to be more responsive to customers, more engaging to employees and as adaptable as possible to what's next. Quickbase helps nearly 6,000 customers, including over 80 percent of the Fortune 50. Visit quickbase.com to learn more.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: